Dissecting the dendritic cell controversy in chronic hepatitis B virus infection

Area of Science:

• Immunology
• Hepatology
• Vaccinology

Background:

• Therapeutic vaccines require functional dendritic cells (DCs) to stimulate T-cell immunity.
• The role of DCs in chronic hepatitis B virus (HBV) infection remains debated.
• Understanding DC function is crucial for developing effective HBV therapies.

Purpose of the Study:

• To synthesize findings from multiple studies on DC function in chronic HBV patients.
• To identify consistent observations regarding DC performance in HBV infection.
• To clarify discrepancies between in vivo and in vitro data on DC behavior.

Main Methods:

• Systematic review and meta-analysis of studies investigating DC frequency and function in chronic HBV patients.
• Comparison of myeloid and plasmacytoid DC function between HBV-infected individuals and healthy donors.
• Correlation analysis of DC function parameters with liver inflammation and viral load.

Main Results:

• Frequency and function of myeloid and plasmacytoid DCs were largely preserved in chronic HBV patients compared to healthy controls.
• A notable exception was reduced Interferon-alpha (IFN-α) production by plasmacytoid DCs in HBV patients.
• Reduced IFN-α production correlated with liver inflammation but not viral load, indicating limited impact of viral antigens on DC function in vivo.
• In vitro studies showing impaired DC function upon exposure to HBV differ from in vivo findings.

Conclusions:

• Dendritic cell function is generally maintained in chronic HBV infection, contrary to some previous assumptions.
• Reduced IFN-α production by plasmacytoid DCs is a specific defect linked to liver inflammation, not directly to viral antigens.
• Discrepancies in the literature may stem from variations in experimental assays and in vitro versus in vivo study designs.